Annuity-Based Pricing Models Could Mean Problems For Small Biotechs
Interest in annuity payment models is growing among companies and payers, but such models could be risk financial viability of small biotechs.
You may also be interested in...
New medicines under evaluation at the European Medicines Agency.
The final text brings some changes, including the introduction of an escalation process when companies and NHS England cannot agree.
European industry association wants global convergence on development requirements, though the European Medicines Agency says that this would prove challenging.